Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Aroa Biosurgery Ltd ( (AU:ARX) ) is now available.
Aroa Biosurgery Ltd announced a correction to their previously released Appendix 3H regarding the cessation of securities, indicating a misclassification of 245,955 securities that were incorrectly lapsed from ARXAAH instead of ARXAAI. This correction does not affect other cessations included in the original document.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery is a company specializing in soft-tissue regeneration, focusing on developing, manufacturing, and distributing medical and surgical products aimed at improving healing in complex wounds and soft tissue reconstruction. Their products utilize a proprietary AROA ECM technology platform, derived from ovine forestomach, and are distributed globally, with a significant market presence in the United States.
Average Trading Volume: 269,731
Technical Sentiment Signal: Buy
Current Market Cap: A$198.4M
See more insights into ARX stock on TipRanks’ Stock Analysis page.